Common Contracts
1 similar Stockholders Merger contracts
Assertio Therapeutics, Inc. (‘‘Assertio Therapeutics’’ or ‘‘Assertio’’) entered into an Agreement and PlanStockholders Merger • April 1st, 2020
of Merger dated as of March 16, 2020, which is referred to in this Joint Proxy Statement/Prospectus as the ‘‘Merger Agreement,’’ with Zyla Life Sciences (‘‘Zyla’’) and certain wholly-owned subsidiaries of Assertio formed to effectuate the Merger Agreement. Pursuant to the Merger Agreement and through a series of transactions described in this Joint Proxy Statement/Prospectus and referred to as the ‘‘Merger,’’ Zyla and Assertio will become wholly-owned subsidiaries of Assertio Holdings, Inc. (‘‘Assertio Holdings’’), with Assertio Holdings assuming Assertio’s listing on the Nasdaq Stock Market. The Merger Agreement is attached as Annex A to this Joint Proxy Statement/Prospectus and is incorporated into this Joint Proxy Statement/Prospectus by reference. This Joint Proxy Statement/Prospectus describes the Merger Agreement, the Merger and the transactions related to the Merger in detail and provides information concerning the annual meeting of Assertio stockholders (the ‘‘Assertio Annual M
